Currently, the focus is on defining sarcomas based on their histologic subtype, molecular profile and genetic changes, rather than their anatomic origin, which will aid the development of novel therapies, like MDM2 and CDK4/6 inhibitors. This evidence concerns the gene CDK4 and sarcoma.